



11 January 2016

ASX ANNOUNCEMENT

Medical Advisory Board for Chronic Heart Failure Established

Brisbane, Australia and Carlsbad, CA - **ImpediMed Limited** (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into agreements to establish a Medical Advisory Board to advise the Company on the design of clinical trials for the use of bioimpedance spectroscopy (BIS) in fluid detection for chronic heart failure patients.

The Medical Advisory Board will work closely with Laura Mauri, MD, MSc, Chief Scientific Adviser at the Harvard Clinical Research Institute and Professor of Medicine at Harvard Medical School, on how to best incorporate BIS in fluid monitoring and management of chronic heart failure patients.

"Management of heart failure is currently a major challenge for patients, their physicians and health care systems," said Dr. Mauri. "We intend to work together to develop clinical studies that will establish whether detection of fluid overload with this non-invasive technology can be used to improve care."

Medical Advisory Board members include:

- Paul Friedman, MD, Vice Chair, Department of Cardiovascular Medicine, Medical Director, Remote Monitoring, Mayo Clinic
- Roy Small, MD, FACC, FSCAI, Medical Director of Clinical Research, Heart Failure Clinic, Lancaster General Hospital
- J. Thomas Heywood, MD, Director, Heart Failure Recovery and Research Program, Scripps Health
- Andrew Accardi, MD, Chairman of Emergency Medicine, Scripps Memorial Hospital Encinitas

The Company has acquired an 510(k) clearance for using bioimpedance for monitoring and management of patients with fluid management problems; including patients living with heart failure, end-stage renal disease, patients recovering from coronary artery disease related events and patients suffering from recurrent dehydration.

"If this technology has the ability to measure alterations in fluid levels accurately over time, it has the potential to significantly improve the delivery of care for heart failure patients," said Dr. Small.

- ENDS -

Richard Carreon
Managing Director & CEO

For further information contact:

Richard Carreon, ImpediMed Managing Director & CEO

Morten Vigeland, ImpediMed CFO

T: +1 (760) 585-2100

Kyahn Williamson, Buchan

Investor and Media Relations

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

For more information, visit: www.impedimed.com.au